Special drug use Surveillance for EFIENT Tablets- Patient with ischemic cerebrovascular disease with a high risk of ischemic stroke
Not Applicable
Recruiting
- Conditions
- Ischemic cerebrovascular disease (associated with large-artery atherosclerosis or small-vessel occlu
- Registration Number
- JPRN-jRCT2031220131
- Lead Sponsor
- Matsuoka Yomei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
Patients who fulfilled the following criteria:
(1) Patients with ischemic cerebrovascular disease associated with large-artery atherosclerosis or small-vessel occlusion (restricted to cases with a high risk of ischemic stroke*1), who were administered EFIENT for the first time
*1: Patients with either hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease or a history of ischemic stroke before the last episode of attack
(2) Patients who started administration of EFIENT tablet during the contract period (contract period based on the contract with each medical site) and until 30/June/2023
(3) Patients from whom written informed consent was obtained
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method